RAC 2.92% $1.94 race oncology ltd

Ann: Zantrene AML trial in Israel advances to Phase 2, page-152

  1. 6,742 Posts.
    lightbulb Created with Sketch. 1712
    Sorry if I didn’t understand the response but I think my question is not answered so asking again, why did you say “…it is not on any approval pathway”?
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.